Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research.
Otlertuzumab (TRU-016) in combination with Rituximab , Rapamycin , or Bendamustine increases cell killing of NHL cells[2].Otlertuzumab has the ability to bind to and kill CD37+ cells[3].
Otlertuzumab (TRU-016) in combination with Bendamustine displays greater anti-tumor activity than either agent alone against a follicular lymphoma tumor model in SCID mice[2].Otlertuzumab shows significant antitumor activity in mice bearing Ramos or Daudi tumor xenografts[3].
References:
[1]. Byrd JC, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8.
[2]. Baum P R, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 2009, 27(15_suppl): 8571-8571. [3]. Cerveny C G, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. Journal of Clinical Oncology, 2008, 26(15_suppl): 3074-3074.